retatrutide clinical trials latest This data from Phase 3 for was announced yesterday at @amdiabetesassn #ADA2026 ✓ We are fortunate to be living in a time where there multiple medications which safely reduce Looking forward to when #retatrutide's

Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory (2025) ACLM, ASN, OMA, TOS GLP-1 Dietary Recommendations for Management of Gastrointestinal Symptoms in Patients on GLP-1 Receptor Agonist Therapy (2024) Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists (2024) GLP-1

A program starting at $179 in month one may cost $299 or more by month four as your dose increases

Congratulations

Until similar data exists for Retatrutide, there remains an open question about its cardiovascular safety and potential benefit, particularly given the theoretical cardiovascular considerations around glucagon receptor activation

Including a protein source at every meal and snack helps maintain consistent intake even when appetite fluctuates

While no serious safety signals unique to retatrutide have been identified in Phase 2 data, the glucagon receptor agonism component raises theoretical considerations around hepatic glucose output and potential effects on heart rate, which are being monitored closely in ongoing Phase 3 trials